Haris Muhammad, Mukhtar Sameen, Mohiuddin Mubashir, Amir Suhaina, Laique Fatima, Azam Muhammad Mazhar, Giri Bibek
Department of Medicine Dow University of Health Sciences Karachi Sindh Pakistan.
Research Institute for Collaborative Development Kathmandu Bagmati Nepal.
Health Sci Rep. 2025 Mar 2;8(3):e70513. doi: 10.1002/hsr2.70513. eCollection 2025 Mar.
Postpartum depression (PPD) is a significant concern globally, emerging from various factors including hormonal changes, genetic influences, and environmental stressors. Conventional treatments such as psychotherapy and antidepressants have been the standard approach, but the recent U.S. Food and Drug Administration (FDA) approval of zuranolone presents a promising alternative with rapid onset of action and potential for increased treatment accessibility. This review aims to evaluate the efficacy and safety of zuranolone in treating PPD, considering its impact on symptom relief and patient outcomes.
This review examines the multifaceted nature of PPD, focusing on its epidemiology, pathophysiology, and therapeutic interventions. Relevant literature was identified through systematic searches of databases, including PubMed and Google Scholar, using keywords related to PPD, hormonal changes, genetic factors, and treatment modalities.
Two rigorous phase 3 trials involving female participants diagnosed with PPD demonstrated that patients treated with zuranolone exhibited significantly greater improvement in depressive symptoms compared to those receiving a placebo. The treatment effect persisted 4 weeks after the last dose of zuranolone, indicating sustained benefits. Zuranolone showed notable effectiveness in reducing PPD symptoms as early as the third day of therapy. Its ease of administration, dosage flexibility, and potential for early intervention contribute to its promise in addressing severe PPD.
PPD poses a significant challenge globally, and zuranolone represents a historic advancement in its treatment. While conventional therapies remain vital, zuranolone offers rapid relief and increased treatment accessibility. However, concerns regarding its safety for breastfeeding women and potential side effects necessitate further research and cautious use. Despite these challenges, zuranolone offers hope for improved outcomes and enhanced quality of life for individuals affected by PPD.
产后抑郁症（PPD）是全球范围内的一个重大问题，其产生受多种因素影响，包括激素变化、遗传因素和环境压力源。心理治疗和抗抑郁药等传统治疗方法一直是标准治疗手段，但美国食品药品监督管理局（FDA）最近批准的 zuranolone 是一种有前景的替代药物，它起效迅速，且有可能提高治疗的可及性。本综述旨在评估 zuranolone 治疗 PPD 的疗效和安全性，同时考虑其对症状缓解和患者预后的影响。
本综述研究了 PPD 的多方面性质，重点关注其流行病学、病理生理学和治疗干预措施。通过系统检索数据库（包括 PubMed 和谷歌学术），使用与 PPD、激素变化、遗传因素和治疗方式相关的关键词，确定了相关文献。
两项针对被诊断为 PPD 的女性参与者的严格 3 期试验表明，与接受安慰剂的患者相比，接受 zuranolone 治疗的患者抑郁症状有显著改善。在最后一剂 zuranolone 后 4 周，治疗效果仍然存在，表明有持续的益处。Zuranolone 早在治疗第三天就显示出在减轻 PPD 症状方面的显著效果。其给药方便、剂量灵活以及早期干预的潜力使其在治疗重度 PPD 方面颇具前景。
PPD 在全球范围内构成重大挑战，而 zuranolone 代表了其治疗方面的一项历史性进展。虽然传统疗法仍然至关重要，但 zuranolone 能提供快速缓解且提高治疗的可及性。然而，对于哺乳期妇女的安全性及其潜在副作用的担忧需要进一步研究并谨慎使用。尽管存在这些挑战，zuranolone 为改善受 PPD 影响个体的预后和提高生活质量带来了希望。
